Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome

[1]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[2]  Lynn A. Hyde,et al.  Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and coordination , 2011, Pharmacology Biochemistry and Behavior.

[3]  Richard Paylor,et al.  Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic‐like responses , 2011, Autism research : official journal of the International Society for Autism Research.

[4]  M. Bear,et al.  Mechanism-based approaches to treating fragile X. , 2010, Pharmacology & therapeutics.

[5]  R. Paylor,et al.  Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety , 2009, Psychopharmacology.

[6]  E. Wirrell.  BEHAVIORAL ASPECTS OF EPILEPSY: PRINCIPLES AND PRACTICE , 2009, Neurology.

[7]  D. Nelson,et al.  Reversal of sensorimotor gating abnormalities in Fmr1 knockout mice carrying a human Fmr1 transgene. , 2008, Behavioral neuroscience.

[8]  Steve D. M. Brown,et al.  Reliability, robustness, and reproducibility in mouse behavioral phenotyping: a cross-laboratory study. , 2008, Physiological genomics.

[9]  S. Ito,et al.  Pharmacological Effects of the Metabotropic Glutamate Receptor 1 Antagonist Compared with Those of the Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 2/3 Agonist in Rodents: Detailed Investigations with a Selective Allosteric Metabotropic Glutamate Receptor 1 Antago , 2008, Journal of Pharmacology and Experimental Therapeutics.

[10]  Chris I. De Zeeuw,et al.  Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice , 2008, Neurobiology of Disease.

[11]  D. Nelson,et al.  Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. , 2008, Behavioral neuroscience.

[12]  C. Goetz,et al.  FMR1 CGG repeat length predicts motor dysfunction in premutation carriers , 2008, Neurology.

[13]  M. Strawderman,et al.  Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. , 2008, Behavioral neuroscience.

[14]  S. Rivera,et al.  The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments , 2008 .

[15]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[16]  M. Millecamps,et al.  Decreased Nociceptive Sensitization in Mice Lacking the Fragile X Mental Retardation Protein: Role of mGluR1/5 and mTOR , 2007, The Journal of Neuroscience.

[17]  Lexin Li,et al.  CGG repeat length correlates with age of onset of motor signs of the fragile X‐associated tremor/ataxia syndrome (FXTAS) , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[18]  Christina Gross,et al.  Dysregulated Metabotropic Glutamate Receptor-Dependent Translation of AMPA Receptor and Postsynaptic Density-95 mRNAs at Synapses in a Mouse Model of Fragile X Syndrome , 2007, The Journal of Neuroscience.

[19]  G. Birk,et al.  The Selective mGlu5 Receptor Antagonist MTEP, Similar to NMDA Receptor Antagonists, Induces Social Isolation in Rats , 2007, Neuropsychopharmacology.

[20]  P. Popik,et al.  Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests , 2007, European Neuropsychopharmacology.

[21]  E. Burón,et al.  Antiaggressive effects of MPEP, a selective antagonist of mGlu5 receptors, in agonistic interactions between male mice. , 2006, European journal of pharmacology.

[22]  Michael Lardelli,et al.  Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. , 2006, Human molecular genetics.

[23]  G. Fox,et al.  Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A‐841720, a novel non‐competitive mGluR1 receptor antagonist , 2006, British journal of pharmacology.

[24]  J. Crabbe,et al.  Stability of inbred mouse strain differences in behavior and brain size between laboratories and across decades , 2006, Proceedings of the National Academy of Sciences.

[25]  K. Hargreaves,et al.  The RNA binding and transport proteins staufen and fragile X mental retardation protein are expressed by rat primary afferent neurons and localize to peripheral and central axons , 2006, Neuroscience.

[26]  L. Volk,et al.  Differential roles for group 1 mGluR subtypes in induction and expression of chemically induced hippocampal long-term depression. , 2006, Journal of neurophysiology.

[27]  Mitchell Glickstein,et al.  Thinking about the cerebellum. , 2006, Brain : a journal of neurology.

[28]  K. Hsu,et al.  Sustained activation of metabotropic glutamate receptor 5 and protein tyrosine phosphatases mediate the expression of (S)‐3,5‐dihydroxyphenylglycine‐induced long‐term depression in the hippocampal CA1 region , 2006, Journal of neurochemistry.

[29]  M. Tranfaglia,et al.  Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP , 2005, Neuropharmacology.

[30]  R. Paylor,et al.  Altered anxiety‐related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome , 2005, Genes, brain, and behavior.

[31]  M. Zhuo,et al.  Deficits in Trace Fear Memory and Long-Term Potentiation in a Mouse Model for Fragile X Syndrome , 2005, The Journal of Neuroscience.

[32]  E. De Schutter,et al.  Deletion of FMR1 in Purkinje Cells Enhances Parallel Fiber LTD, Enlarges Spines, and Attenuates Cerebellar Eyelid Conditioning in Fragile X Syndrome , 2005, Neuron.

[33]  W. Danysz,et al.  Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. , 2005, European journal of pharmacology.

[34]  Yan Wang,et al.  Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome , 2005, Neuron.

[35]  Larry F Hughes,et al.  Hearing in laboratory animals: strain differences and nonauditory effects of noise. , 2005, Comparative medicine.

[36]  R. E. Brown,et al.  A phenotypic and molecular characterization of the fmr1‐tm1Cgr Fragile X mouse , 2004, Genes, brain, and behavior.

[37]  Eric Klann,et al.  Activation of the Phosphoinositide 3-kinase–akt–mammalian Target of Rapamycin Signaling Pathway Is Required for Metabotropic Glutamate Receptor-dependent Long-term Depression , 2022 .

[38]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[39]  Alcino J. Silva,et al.  Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice , 2004, Molecular Psychiatry.

[40]  K. Hsu,et al.  Rap1-induced p38 Mitogen-activated Protein Kinase Activation Facilitates AMPA Receptor Trafficking via the GDI·Rab5 Complex , 2004, Journal of Biological Chemistry.

[41]  Danuta Z Loesch,et al.  Phenotypic variation and FMRP levels in fragile X. , 2004, Mental retardation and developmental disabilities research reviews.

[42]  B. Meldrum,et al.  Glutamate metabotropic receptors as targets for drug therapy in epilepsy. , 2003, European journal of pharmacology.

[43]  P. Conn,et al.  Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents , 2003, Journal of Pharmacology and Experimental Therapeutics.

[44]  D. Hatton,et al.  Self‐injurious behavior in young boys with fragile X syndrome , 2003, American journal of medical genetics. Part A.

[45]  B. D. Vries,et al.  Fragile X syndrome: diagnosis, treatment and research , 2003, Human Genetics.

[46]  C. B. Smith,et al.  Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Jesse Brodkin,et al.  Anxiolytic-like activity of the mGluR5 antagonist MPEP A comparison with diazepam and buspirone , 2002, Pharmacology Biochemistry and Behavior.

[48]  P. Saggau,et al.  Modulation of Presynaptic Calcium Transients by Metabotropic Glutamate Receptor Activation: A Differential Role in Acute Depression of Synaptic Transmission and Long-Term Depression , 2002, The Journal of Neuroscience.

[49]  Mark F. Bear,et al.  Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Darci M. Nielsen,et al.  Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome , 2002, Brain Research.

[51]  A. Reiss,et al.  The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. , 2001, Pediatrics.

[52]  Richard Paylor,et al.  The use of behavioral test batteries: Effects of training history , 2001, Physiology & Behavior.

[53]  M. Bear,et al.  Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. , 2001, Journal of neurophysiology.

[54]  D. Condorelli,et al.  Expression of metabotropic glutamate receptors in the rat and human testis. , 2001, The Journal of endocrinology.

[55]  L. Chen,et al.  Fragile X mice develop sensory hyperreactivity to auditory stimuli , 2001, Neuroscience.

[56]  F. Gasparini,et al.  Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist , 2001, British journal of pharmacology.

[57]  R. Gereau,et al.  Peripheral group I metabotropic glutamate receptors modulate nociception in mice , 2001, Nature Neuroscience.

[58]  W. Spooren,et al.  Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. , 2000, The Journal of pharmacology and experimental therapeutics.

[59]  D. Nelson,et al.  (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. , 2000, Human molecular genetics.

[60]  Raffaele Ferri,et al.  Audiogenic Seizures Susceptibility in Transgenic Mice with Fragile X Syndrome , 2000, Epilepsia.

[61]  J. Crabbe,et al.  Genetics of mouse behavior: interactions with laboratory environment. , 1999, Science.

[62]  B. Oostra,et al.  FMRP expression as a potential prognostic indicator in fragile X syndrome. , 1999, American journal of medical genetics.

[63]  A. Reiss,et al.  Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. , 1999, American journal of medical genetics.

[64]  Jacqueline N. Crawley,et al.  A Proposed Test Battery and Constellations of Specific Behavioral Paradigms to Investigate the Behavioral Phenotypes of Transgenic and Knockout Mice , 1997, Hormones and Behavior.

[65]  G. Lombardi,et al.  Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist. , 1997, The Journal of pharmacology and experimental therapeutics.

[66]  R Lujan,et al.  Perisynaptic Location of Metabotropic Glutamate Receptors mGluR1 and mGluR5 on Dendrites and Dendritic Spines in the Rat Hippocampus , 1996, The European journal of neuroscience.

[67]  A. Reiss,et al.  Contribution of the FMR1 gene mutation to human intellectual dysfunction , 1995, Nature Genetics.

[68]  I. Gyertyán,et al.  Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying , 1995, Behavioural pharmacology.

[69]  G. Collingridge,et al.  Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1 , 1994, Nature.

[70]  S. Tonegawa,et al.  Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice , 1994, Cell.

[71]  Guy Nagels,et al.  Fmr1 knockout mice: A model to study fragile X mental retardation , 1994, Cell.

[72]  G. Sales,et al.  Sound levels in rooms housing laboratory animals: An uncontrolled daily variable , 1993, Physiology & Behavior.

[73]  S. Handley,et al.  Evaluation of marble-burying behavior as a model of anxiety , 1991, Pharmacology Biochemistry and Behavior.

[74]  D. Treit,et al.  Thigmotaxis as a test for anxiolytic activity in rats , 1988, Pharmacology Biochemistry and Behavior.

[75]  G. Sales,et al.  Environmental ultrasound in laboratories and animal houses: a possible cause for concern in the welfare and use of laboratory animals , 1988, Laboratory animals.

[76]  J. Bregman,et al.  Fragile-X syndrome: variability of phenotypic expression. , 1987, Journal of the American Academy of Child and Adolescent Psychiatry.

[77]  C. D. Stern,et al.  Handbook of Chemical Neuroanatomy Methods in Chemical Neuroanatomy. Edited by A. Bjorklund and T. Hokfelt. Elsevier, Amsterdam, 1983. Cloth bound, 548 pp. UK £140. (Volume 1 in the series). , 1986, Neurochemistry International.

[78]  Silverman,et al.  Fragile X Syndrome Diagnosis Treatment And Research , 2016 .

[79]  M. Geyer,et al.  Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice , 2009, Neurotoxicity Research.

[80]  D. Riva,et al.  The contribution of the cerebellum to mental and social functions in developmental age , 2007, Human Physiology.

[81]  A. Megens,et al.  Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test , 2004, Psychopharmacology.

[82]  Wim E Crusio,et al.  Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse , 2002, Hippocampus.

[83]  R. Shigemoto,et al.  Chapter III Metabotropic glutamate receptors — immunocytochemical and in situ hybridization analyses , 2000 .

[84]  M. Partington,et al.  The fragile X syndrome II: preliminary data on growth and development in males. , 1984, American journal of medical genetics.

[85]  S. Ferguson,et al.  Associate editor: P. Molenaar , 2022 .